pending for release
RNAseq of MCL cell lines
This study provides bulk RNA sequencing data from Mino and Jeko-1 mantle cell lymphoma (MCL) cell lines treated with CDK9 inhibitors, including the novel compound YX0798. CDK9 is a key regulator of RNA polymerase II–mediated transcription, and its inhibition disrupts transcriptional programs critical for tumor survival. The dataset captures transcriptomic changes associated with CDK9 inhibition, including downregulation of oncogenic drivers such as MYC and MCL-1. These data support mechanistic studies of transcriptional reprogramming and therapeutic vulnerability in aggressive MCL.
- Type: RNASeq
- Archiver: European Genome-Phenome Archive (EGA)
| Publications | Citations |
|---|---|
|
YX0798 is a highly potent, selective, and orally effective CDK9 inhibitor for treating aggressive lymphoma.
Blood Adv 9: 2025 4963-4976 |
0 |
